Neural calcium-activated neutral proteinase inhibitors
AssigneeThe McLean Hospital Corporation
InventorsRalph A. Nixon, Kiyoshi H. Takeuchi
Life of this patent
Estimating the term…
Abstract
This invention is directed to two highly purified neural calcium-activated neutral proteinase (CANP or calpain) inhibitors, known as high molecular weight calpastatin (HMWC) and low molecular weight calpastatin (LMWC). The invention also relates to recombinant DNA molecules which code for, and antibodies which bind to these proteins. The present invention is further directed to the use of these calpastatin proteins.
Claims2
An antibody specifically immunoreactive with an immunogen, wherein said immunogen consists essentially of a substantially purified, low molecular weight calpastatin with a molecular weight of about 60 kilodaltons, as determined by gel filtration, and consisting of a dimer of about 31 kilodalton subunits, as determined by SDS PAGE under reducing conditions, and wherein said calpastatin has a pI range of 4.2-4.7 on an isoelectric focusing gel and an N-terminal amino acid sequence as follows:
- NH.sub.2 -X-Glu-Lys-Glu-Thr-Lys-Glu-Glu-Gly-Lys-Pro-Lys-Gln-Gln-Gln-X-X-Lys-Glu-Lys (SEQ ID NO:
- 2)
- wherein X represents an unknown amino acid residue;
- wherein said calpastatin has the following amino acid composition:
- ______________________________________ Mole % ______________________________________ Asx 8.4 Thr 3.6 Ser 10.3 Glx 17.1 Pro 5 Gly 16.4 Ala 6.4 Cys/2 0 Val 4.3 Met 0.9 Ile 3.3 Leu 3.1 Tyr 2.7 Phe 7 Lys 1.3 His 4 ______________________________________
- wherein:
- Asx=sum of aspartic acid (D) and asparagine (N), and
- Glx=sum of glutamic acid (E) and glutamine (Q);
- and wherein said calpastatin is capable of inhibiting calcium-activated neutral proteinase activity.
Dependencies are inferred from the claim text.